US 12,331,029 B2
Orexin 1 receptor antagonists
Giles Albert Brown, Cambridge (GB); Miles Stuart Congreve, Cambridge (GB); John Andrew Christopher, Cambridge (GB); Nigel Alan Swain, Cambridge (GB); Sarah Joanne Bucknell, Cambridge (GB); Anne Mary Stephenson, Cambridge (GB); Benjamin Gerald Tehan, Cambridge (GB); Mark Mills, Nottingham (GB); and Anil Patel, Nottingham (GB)
Assigned to Nxera Pharma UK Limited, Cambridge (GB)
Appl. No. 17/413,369
Filed by NXERA PHARMA UK LIMITED, Cambridge (GB)
PCT Filed Dec. 16, 2019, PCT No. PCT/GB2019/053557
§ 371(c)(1), (2) Date Jun. 11, 2021,
PCT Pub. No. WO2020/120994, PCT Pub. Date Jun. 18, 2020.
Claims priority of application No. 1820458 (GB), filed on Dec. 14, 2018.
Prior Publication US 2022/0041573 A1, Feb. 10, 2022
Int. Cl. C07D 401/04 (2006.01); C07D 239/26 (2006.01); C07D 241/12 (2006.01); C07D 401/12 (2006.01)
CPC C07D 401/04 (2013.01) [C07D 239/26 (2013.01); C07D 241/12 (2013.01); C07D 401/12 (2013.01)] 17 Claims
 
1. A compound of formula (1):

OG Complex Work Unit Chemistry
or a salt thereof, wherein
W is N or CR5;
X is N or CR6;
Y is CH2;
Z is CR7 or N;
R1 is H or a halogen;
R2 is a 5-or 6-membered heteroaryl ring, containing two or three nitrogen atoms, and optionally substituted with one or more fluorine atoms;
R3 is H or a halogen;
R4 is H or a halogen;
R5 is selected from H; halogen; C1-C3 alkyl, optionally substituted with OMe or one or more halogen groups; and C1-C3 alkoxy, optionally substituted with one or more halogen groups;
R6 is selected from H; halogen; C1-C3 alkyl, optionally substituted with OMe or one or more halogen groups; and C1-C3 alkoxy, optionally substituted with one or more halogen groups; and
R7 is H or a halogen.